The pipeline and market for psoriasis drugs
1 Feb 2024
Nature.com
![The pipeline and market for psoriasis drugs](/thumb/phpThumb.php?src=%2Fuploads%2Fnews%2F46%2F4628%2F2%2F4628220-the-pipeline-and-market-for-psoriasis-drugs.jpg&w=706&hash=e98c2be9d4cef82ca1f142625fb24e11)
Discover the world’s best science and medicine | Nature.com
Psoriasis is a chronic T-lymphocyte-mediated inflammatory disorder that affects 2–3% of the population globally. It is associated with abnormal keratinocyte proliferation, and is clinically characterized by erythematous, clearly demarcated papules and rounded plaques. Approximately 75% of patients with psoriasis will have at least one comorbid condition, with psoriatic arthritis being the most common.
Competing Interests
The authors declare no competing interests.